INTRODUCTION AND AIMS:
The search of a phosphate binder (PB) to improve adherence remains an open issue. Studies in real clinical practice are necessary to understand the influence of patients' preferences to accept a PB. Aims: To describe the phosphorous control of Velphoro in HD patients, as well as adherence, acceptance by the patient and strategies that support compliance in clinical practice. METHODS: Prospective analysis of a cohort of 105 treated with PB patients on HD . From those,57 patients were switched to Velphoro and 48 patients maintained their baseline treatment. We analyzed the P values for 2 months, the adherence to the treatment using the SMAQ questionnaire, preferences in the administration mode, side effects, and strategy to improve its compliance. RESULTS: Even in previous non-compliant hyperphospatemic patients, the percentage of patients with controlled P (<5 mg/dl) increased significantly in the Velphoro users group (62,1% to 93,1%,p<0,001) , but not in the control group (83% to 85%, P ¼NS) at 2 months. The average of daily tablets decreased significantly in the Velphoro group (7,2 to 2,6 comp, p<0,001), but not in the control group (5, 6 to 5, 7 , p¼NS) (fig 1) .The use of Velphoro increase the adherence according to the SMAQ questionnaire (OR 13.1, p <0.001) at 2 months and 100% of the patients have been able to control their P using only one PB. Patients were informed about various modes of intake (swallow/ chew), and adapting it to the preferences of the patient (swallowed 89% compared to chewing 11%), improved the acceptance (44.7% to 78%). 15% of the patients experienced side effects (none serious): diarrhea, constipation and thirst) and in 6.8% Velphoro was discontinued for this reason. Average age 63.39 years in ability, its lower number of tablets and its intake flexibility to adapt it to the patient's preferences. Figure 1 
Decreased kidney function, as seen in CKD patients, has a profound effect on a multitude of interlinked secondary pathophysiological abnormalities, including metabolic acidemia, mineral and bone disorder (CKD-MBD) which comprise secondary hyperparathyroidism (SHPT) and extraskeletal calcification. These disorders contribute to increased morbidity and mortality. The aim of this study is to develop a comprehensive mathematical model describing bone remodeling and mineral homeostasis that enables in silico exploration of the ramifications of disease-and therapy-induced disturbances, with the goal of expanding knowledge and providing a rationale for new therapeutics. METHODS: A mechanistic model describing bone remodel activities is developed to quantify the interrelations of the basic multicellular unit (BMU), namely osteoclasts, osteoblasts, and osteocytes. The synchronized activities of these BMUs are mediated by cell-cell (RANK-RANKL-OPG) and intracellular (Runx-2-CREB-Bcl-2) signaling pathways, cytokines (MCSF, TGF b ), PTH, sclerostin, and endocrine and paracrine feedbacks. The applicability of the resulting model is demonstrated by comparing model predictions of different pathologies (e.g., PHPT and SHPT, chronic metabolic acidemia, uremia) to clinical observations. RESULTS: Our model qualitatively predicts clinically observed responses to induced PHPT and SHPT and acidemia, and their effects on extracellular calcium (Ca) and phosphate (PO 4 ) levels and bone mineral density (BMD). We accurately predict differential responses of osteo-anabolic and catabolic effects of continuously and intermittently elevated level of PTH, respectively. In addition, the model also predicts the catabolic effect of metabolic acidosis on bone remodeling, including decreased BMD, and increased efflux of Ca and PO 4 . Using the model, short-and long-term in silico study of disease-induced primary, secondary or combination of disturbances can be undertaken to understand and investigate the effectiveness of different therapeutic interventions. CONCLUSIONS: The model can be used to simulate bone remodeling homeostasis and to explore therapeutic and pathophysiological states of the various diseases through (1) in silico assessments of effect of therapeutic modality for CKD patients and other patients with metabolic bone diseases, (2) understanding intended and unintended disease-specific variations and alterations, (3) optimizing and personalizing dosing regimens to achieve acceptable target goals (e.g., maintenance of BMD), (4) simulation of infeasible clinical tests, and (5) 
The 3rd generation PTH assays detect the only total bioactive 1-84 fragment. Since standardization is still lacking, each new PTH assay requires to establish reference values and to assess the impact in the medical care of the mineral and bone disorders in CKD5 patients. METHODS: Serum PTH levels were measured with Lumipulse w-PTHV C chemiluminescent enzyme immunoassay on Lumipulse G600V C II from Fujirebio in a healthy population. We enrolled 269 healthy subjects from Montpellier (France) and 184 healthy subjects from Liège (Belgium) that presented normal calcium and phosphorus levels, eGFR > 60 mL/min/1.73 m 2 and 25(OH) vitamin D levels > 30 ng/mL. In addition PTH levels were determined in 119 hemodialyzed patients from the CHU Lapeyronie (Montpellier) undergoing dialysis three times a week and classified according to the KDIGO recommendation which suggest that PTH should be maintained in the range of approximately two to nine times the upper normal limit for the assay. RESULTS: The Fujirebio Lumipulse 3 rd PTH reference range, established in 439 Individuals after elimination of the outliers according to the Horn estimation method was found to be 6.5 (90%CI: 6.0-7.0) -33.9 (90% CI: 31.6-36.3) pg/mL. In hemodialysis patients, the Passing-Bablock regression between 3 rd generation PTH from Fujirebio and DiaSorin was DiaSorin¼1.01 x Fujirebio -2.4 with a slope not different from 1.0 (95%CI: 0.96-1.04) and an intercept not different from 0.0, ranging from -6.0 to 0.1. Hemodialysis patients with a PTH concentration below 2 fold of upper limit, within the KDIGO range and upper 9 fold upper limit were respectively 28.6 %, 55.4%, 16% using Fujirebio and 26.1%, 52.1%and 21.8 % using Diasorin assay and its upper limit of normality (ULN) previously determined. Taking into account the 90% CI of the ULN value, the kappa coefficient reveals a very good agreement (0.964), with only 2 discordant patients CONCLUSIONS: The established reference range was determined in a healthy population of French and Belgian Caucasians with the 3 rd generation PTH assay from Fujirebio. In hemodialysis population, the 3 rd generation assay from Fujirebio and from DiaSorin are quite similar. According to the 90% confidence interval of the ULN of the ranges, the error rate for classification of hemodialysis patients according to the KDIGO guidelines, was less than 2%.
FP392 FIBROBLAST GROWTH FACTOR 23 AND THE RISK OF RENAL REPLACEMENT THERAPY INITIATION IN NON-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS
Cristina Capusa 
INTRODUCTION AND AIMS:
While the relationship between hyperphosphatemia and the risk of chronic kidney disease (CKD) progression is increasingly suggested, data about the impact of elevated serum fibroblast growth factor 23 on the kidney outcome are still scarce. Therefore, the potential association of the baseline serum c-terminal fibroblast growth factor 23 (cFGF23) with poor kidney survival in non-dialysis CKD patients was assessed in this retrospective cohort study.
METHODS: Ninety-one Caucasian adult CKD subjects (59% males, 50% over 60 years-old, 25% diabetes mellitus, 70% in the high and very high risk KDIGO categories) were enrolled. Data on past medical history (CKD-related, comorbidities, chronic medications), physical exam (body mass index, arterial blood pressure), estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (uACR), and laboratory parameters of mineral metabolism, nutritional and inflammation status were extracted from medical files. The time until the start of renal replacement therapy (RRT: hemodialysis, peritoneal dialysis or kidney graft) was the investigated outcome. Both active and passive follow-up methods were used (by phone contact and Romanian Renal Registry database search) to gather information, and survival analysis was performed by Kaplan-Meier analysis and Cox regression models. RESULTS: The median eGFR at baseline was 30 (95%CI 28 to 37) mL/min. During the follow-up period of 4 (2.3;4.4) years, 31% subjects started RRT. They had higher serum cFGF23 (2.8, 95%CI 1.5 to 4.1 vs. 0.7, 95%CI 0.5 to 1.0 pmol/L, p<0.001), phosphate, intact parathyroid hormone, alkaline phosphatase, and albuminuria, but lower eGFR and serum albumin. Shorter RRT-free survival (42; 95%CI 37 to 47 vs. 53; 95%CI 49 to 57 months, p<0.001) was found in patients with higher than median cFGF23 (>0.56 pmol/L). Similarly, the highest quartile of cFGF23 was associated with reduced RRTfree survival as compared to the lowest quartile (36; 95%CI 30 to 43 vs. 52; 95%CI 45 to 58 months, p<0.001). However, after adjustments for covariates in a Cox regression model, cFGF23 level was not retained as an independent predictor of end-stage kidney disease. The RRT initiation was predicted only by eGFR (HR -1.71, 95%CI 0.06 to 0.53; p¼0.002), uACR (HR 0.79; 95%CI 1.5-3.2; p<0.001), and serum phosphate (HR 2.29; 95%CI 1.71 to 57.1; p¼0.01). Of note, in bivariate analysis, significant associations of eGFR with all the other parameters were found. CONCLUSIONS: These findings seem to cast doubt on the independent effect of FGF23 on CKD progression, and point out both to CKD severity at baseline (i.e. lower eGFR and higher albuminuria) and higher serum phosphate as notable risk factors. One possible explanation could be the tight relationships between mineral metabolism parameters and kidney function, which might conceal the contributions of the other individual parameters.
FP393 DOES ACTIVE OR NATIVE VITAMIN D SUPPLEMENTATION IMPROVE ARTERIAL STIFFNESS IN NON-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS?
INTRODUCTION AND AIMS:
Both vitamin D deficiency and arterial stiffness are highly prevalent in chronic kidney disease (CKD) and appears to contribute to the cardiovascular morbidity. As experimental studies advocated a role of vitamin D for arterial health and observational reports sustained a correlation between low serum calcidiol and increased rigidity of arterial wall, but evidence regarding the exogenous vitamin D supplementation's influence are inconsistent or missing, we aimed to investigate the effects of medium-term cholecalciferol and paricalcitol therapy on parameters of arterial stiffness in non-dialysis CKD patients. METHODS: Forty-eight vitamin D-naïve adults with stage 3 to 5 CKD and secondary hyperparathyroidism entered this open-label, active comparator controlled, 1:1 randomized (stratified by the CKD stage), 6-months course trial. Exclusion criteria were: kidney graft, dialysis, presence of native arterio-venous fistula for future hemodialysis, atrial fibrillation, hypercalcemia >10.5mg/dL, hyperphosphatemia >5mg/dL, and treatments with biphosphonates and calcium salts. Subjects were allocated to either oral cholecalciferol 1000 UI/day -C group [n¼24; 61(95%CI 54 to 66) years, 48% males, eGFR 30 (95%CI 25 to 38) mL/min] or paricalcitol 1 mcg/day -P group [n¼24; 64(95%CI 54 to 67) years, 66% males, eGFR 25 (95%CI 22 to 34) mL/min]. Cardioankle vascular index (CAVI) and ankle-brachial index (ABI), measured by automatic waveform analyzer (VaSera VS-1000), were indicative of arterial stiffness at values >9 and >1.3, respectively. Median changes after 6 months vs. baseline (D 6-0 ) in CAVI and ABI were the primary efficacy parameters. Biochemical parameters of mineral metabolism (serum calcidiol, total calcium, phosphate, intact parathyroid hormone -iPTH, and alkaline phosphatase) were also assessed. Mann-Whitney and Wilcoxon paired tests were used for comparisons. RESULTS: No significant differences in demographic and general characteristics existed between groups at baseline. Also, investigated mineral metabolism parameters were comparable before treatment, except for higher iPTH in P group [139 (95%CI 146 to 274) vs. 87 (95%CI 68 to 193) pg/mL; p¼0.001]. Similar proportions of subjects had increased CAVI and ABI (79 vs. 78% and 8 vs. 4% in P and C group, respectively; p>0.05).At the end of study, ABI was lower in P group [1.13 (95%CI 1.02 to 1.15) vs. 1.18 (95%CI 1,10 to 1,20) at baseline; p¼0.003], but did not vary significantly in C group [1,10 (95%CI 1.04 to 1.16) vs. 1.14 (95%CI 1.09 to 1.18); p¼0.27]. Instead, CAVI remained unchanged [9.7 (95%CI 9.0 to 10.9) at 6 months vs. 9.7 (95%CI 9.4 to 10.8) at baseline, after native vitamin D; p¼0.43, and 10.3 (95%CI 9.9 to 11.9) vs. 11.1 (95%CI 10.2 to 12.1) after paricalcitol, respectively; p¼0.19]. Moreover, the median changes did not differ either for CAVI or for ABI (Table) .
